Ovid Therapeutics (OVID) Current Deferred Revenue (2020 - 2025)

Ovid Therapeutics (OVID) posted Current Deferred Revenue of $718000.0 for Q3 2025, little changed on a QoQ basis from $718000.0 in Q2 2025.

Ovid Therapeutics (OVID) Current Deferred Revenue (2020 - 2025) Analysis & Trends

Ovid Therapeutics' Current Deferred Revenue history runs 2 years deep, the most recent figure standing at $718000.0 for Q3 2025.

Quarterly Current Deferred Revenue changed N/A year-over-year to $718000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $718000.0 (changed N/A YoY) and the FY2020 annual result came in at $2.2 million, changed N/A from the prior year.
Current Deferred Revenue was $718000.0 for Q3 2025 at Ovid Therapeutics, roughly flat from $718000.0 in the prior quarter.
Across five years, Current Deferred Revenue topped out at $718000.0 in Q2 2025 and bottomed at $718000.0 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-
10	Ovid Therapeutics	118.66 Mn	-36.86 Mn	-

Download Data